Who owns LianBio, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
No 13D/13G disclosures on record for LianBio.
No holder has disclosed crossing the 5% threshold in filings since December 18, 2024, when our coverage begins.
Every institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of LianBio they hold. Together these 1 managers report 0.01% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| FNY Investment Advisers, LLC | $1K | 14,000 | 0.00% | 0.01% | June 30, 2026 |
Funds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 11 funds hold 3.32% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | $3.03M | 0.02% | 1.88% | September 30, 2023 |
| BlackRock Health Sciences Term Trust | $2.75M | 0.14% | 0.57% | December 31, 2023 |
9 more funds behind a free account
See every fund holding LianBio and what share of its net assets the position represents.
Sign up freeLoading...
